The effectiveness of dexmedetomidine infusion for sedating oral cancer patients undergoing awake fibreoptic nasal intubation
- 1 January 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in European Journal of Anaesthesiology
- Vol. 27 (1), 36-40
- https://doi.org/10.1097/eja.0b013e32832e0d2b
Abstract
Dexmedetomidine is characterized with effects of sedation, analgesia, amnesia and lack of respiratory depression. Hence, it should be suitable for awake fibreoptic intubation (AFOI). We enrolled 30 oral cancer patients with limited mouth openings who were undergoing AFOI for elective surgery. Patients were randomly allocated into two groups; the Dex group (n = 16) that received dexmedetomidine (1.0 microg kg(-1)) infusion and the Control group (n = 14) that received fentanyl (1.0 microg kg(-1)) infusion. Main outcomes were evaluated by grading scores presenting conditions for nasal intubation and postintubation. Other analysed parameters included airway obstruction, haemodynamic changes, consumption time for intubation, amnesia level and satisfaction. Intubation score (1-5) representing condition for nasal intubation was significantly better in the Dex group [2(1-3)] than in the Control group [3(2-5)] (P = 0.001). Postintubation score (1-3) representing tolerance to intubation also showed more favourable results in the Dex group [1(1-3)] than in the Control group [2(2-3)] (P = 0.002). The Dex group showed significantly reduced haemodynamic response to intubation than the Control group. Incidence requiring temporary haemodynamic support was higher in the Dex group but not of significance. Both levels of amnesia and satisfaction score were significant in the Dex group. Other analysed parameters such as consumption time for intubation, airway obstruction score and postoperative adverse events did not differ significantly. Combination of dexmedetomidine loading with topical anaesthesia provides significant benefit for AFOI in intubation condition, patient tolerance, haemodynamic response, amnesia and satisfaction. Dexmedetomidine is effective for AFOI in anticipated difficult airway with only minor and temporary haemodynamic adverse effects.Keywords
This publication has 19 references indexed in Scilit:
- A Comparison of Propofol and Remifentanil Target-Controlled Infusions to Facilitate Fiberoptic Nasotracheal IntubationAnesthesia & Analgesia, 2009
- Intubation of an infant with Pierre Robin sequence under dexmedetomidine sedation using the Shikani Optical Stylet™Acta Anaesthesiologica Scandinavica, 2008
- Dexmedetomidine as sole sedative for awake intubation in management of the critical airwayJournal of Clinical Anesthesia, 2007
- Dexmedetomidine for fiberoptic intubation of a patient with severe mental retardation and atlantoaxial instabilityActa Anaesthesiologica Scandinavica, 2006
- Fiberoptic Intubation with Dexmedetomidine in Two Children with Spinal Cord ImpingementsAnesthesia & Analgesia, 2005
- Dexmedetomidine and Awake Fiberoptic Intubation for Possible Cervical Spine MyelopathyJournal of Neurosurgical Anesthesiology, 2005
- Dexmedetomidine infusion for sedation during fiberoptic intubation: a report of three casesJournal of Clinical Anesthesia, 2004
- Target-controlled infusion of propofol for fibreoptic intubationEuropean Journal of Anaesthesiology, 2003
- Effects of Intravenous Dexmedetomidine in HumansAnesthesiology, 1992
- Dexmedetomidine, an α2-Adrenoceptor Agonist, Reduces Anesthetic Requirements for Patients Undergoing Minor Gynecologic SurgeryAnesthesiology, 1990